Skye Bioscience, Inc. (SKYE)

NGM – Real Time Price. Currency in USD

0.81

-0.07 (-7.56%)

At close: May 12, 2026, 4:00 PM EDT

0.81

-0.00 (-0.42%)

After-hours: May 12, 2026, 7:46 PM EDT

22.04.2026

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Skye Bioscience, Inc. (NASDAQ: SKYE) breached their fiduciary duties to shareholders.

07.04.2026

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present at the GLP-1-Based Therapeutics Summit in Boston, MA, being held April 14-16. Presentation Details Title: Maximizing Efficacy, Minimizing Risk by Leveraging Peripheral CB1 Antagonism in Combination with GLP-1 Agonists to Advance the Obesity Treatment Paradigm Presenter: Punit Dhillon, President & CEO Date: Thursday, April 16, 2026 Time: 1:30 pm About Nimacimab Nimacimab is a potential first-in-class, peripherally-restricted monoclonal antibody inhibitor of the CB1 receptor.

02.04.2026

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study

11.03.2026

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

10.03.2026

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025, along with key accomplishments and upcoming milestones.

05.03.2026

Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Tuesday, March 10th at 1:30 p.m. PT/4:30 p.m.

02.02.2026

Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year

Skye Bioscience, Inc. (NASDAQ: SKYE) on Monday shared interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond proof-of-concept study of nimacimab.

Videos

No Data

There is no data to display

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

10.03.2026

Skye Bioscience, Inc. (SKYE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Skye Bioscience, Inc. (SKYE)

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year

Videos

No Data

Press releases

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year

Videos

No Data

Press releases

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Search stocks

Skye Bioscience, Inc. (SKYE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Skye Bioscience, Inc. (SKYE)

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year

Videos

No Data

Press releases

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year

Videos

No Data

Press releases

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update